|Filed Under:||Medical / Pharmaceutical|
|Posts on Regator:||1127|
|Posts / Week:||4.1|
|Archived Since:||February 24, 2008|
it's been a lot of fun. See ya round. -DrugMonkey
in which a picture is worth a thousand words.... but you need to go read the post by Hermitage. Also, here's a link to the Chronicle bit on the disparity in undergraduate scholarship awards mentioned in the post at The Hermitage.
BikeMonkey Guest Post Believe you me, it does not escape my attention that instead of working on my grant that is due in approx one month's time, I am talking about the Ginther et al report. No, I am not obligated to say jack squatte about it. Show More Summary
A commenter named ES over at writedit's blog asked: I am wondering if I can conduct unfunded research projects using my current RO1 support since I have more experience and more publications on these unfunded projects. In contrast, testing our hypothesis proposed in my funded RO1 is practically not promising. Show More Summary
Unless you have been hiding under a rock, my NIH-focused Reader, you will have heard of the explosive findings of Ginther et al (2011) who reported on an analysis of racial and ethnic disparity in the review and funding of NIH grant applications. There is a lot to discuss about these findings. Show More Summary
I have just been informed that ScienceBlogs will no longer be hosting anonymous or pseudonymous bloggers. In case you are interested, despite extensive communication from many of us as to why we blog under pseudonyms, I have not been given any rationale or reason for this move. Show More Summary
A recent paper from Brents et al. (PubMed) presents the data that we've been hearing about for the past several months. I think leigh of the Neurodynamics blog (see posts on THC and cannabimimetic/JWH-018 pharmacology), may have been...Show More Summary
The NIH has put out a request for information (NOT-OD-11-106) to gain "Input into the Deliberations of the Advisory Committee to the NIH Director Working Group on the Future Biomedical Research Workforce". This blog, its readership and the corner of the blogosphere we inhabit has a slightly greater than passing interest in such matters. Show More Summary
Representative Roscoe Bartlett (R, Maryland) had an Op/Ed bit up in the NYT a few days ago. He's against the use of chimpanzees in research. Fair enough, our elected Representatives are welcome to their opinions. But there were two glaring items that require correction or comment. First, he tells tall tales about Nim. Show More Summary
Go give your answer at The Tightrope blog. I'd say the answer for substance-abuse type disciplines, the answer is no. There do seem to be a lot of K99/R00 folks being hired though.
Commenters Grumble recently grumbled: Yes, but what is the quality of the science when scientists have to spend so much of their time writing grants? Essentially what you are saying is that any PI needs to constantly apply for grants, just get an occasional award to keep the lab afloat. Show More Summary
A visual depiction across the training stages. This is absolute truth. Click for the full image.
Whew, I can feel the keyboards screaming in agony as the OUTRAGED PI's hammer away at their comments. The Rock Talk blog entry is supposed to be about What Can You Do When Two Reviewers Contradict Each Other. Now admittedly, the blog advice is, well, laughable. In this situation we encourage you to use your best judgment. Show More Summary
A towering legendary figure of behavioral pharmacology and the drug abuse sciences has passed on. photo Joseph V. Brady, Ph.D. [Department, PubMed, Neurotree] died Friday July 29, 2011 at the age of 89. He earned his doctorate in 1951...Show More Summary
Check it out!
This is fantastic. ...CSR is piloting a new program that we call the early career reviewer, where we will take complete novice reviewers, people who have not reviewed for NIH before, very early in their career, probably new investigators. More thoughts on the matter from Your Humble Narrator and Prof-Like Substance.
The New York Times had a piece up Sunday that was entitled "An Alarming New Stimulant, Legal in Many States". I was alerted to this by David Kroll who reposted some prior comments at his Take as Directed blog. I've been getting someShow More Summary
Following some chatter at the Rock Talk blog I ran across some very interesting news from the NHLBI: The NHLBI will continue a commitment to help ESIs by a policy of maintaining separate paylines for new competing (Type 1) R01 and First Renewal (Type 2) applications in accordance with NIH guidelines. Show More Summary
GertyZ has a new post up at Balanced Instability which discusses the joys of Indirect Costs in the context of major grant awards, for our purposes we'll focus on the NIH grant. This is not a mere inconvenient detail of little directShow More Summary
The recent meeting of the College on Problems of Drug Dependence featured a very well attended session on the emerging recreational drugs that are best described generically as synthetic cannabis. Popularly these are frequently referred to as K2 or Spice as these seem to be the best known of the initial market branding. Show More Summary